Press Release
3 April 2020
Immunicum AB (publ) Publishes the Annual Report for 2019
Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2019 is now available on the company's website, www.immunicum.com.
The printed Annual Report will be distributed in mid-April 2020 to shareholders who have requested it. For further information, please contact the company by telephone +46 8 732 8400 or e-mail, info@immunicum.com.
This information is information that Immunicum is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 8:00 am CEST on 3 April 2020.
For more information, please contact:
Alex Karlsson-Parra, CSO and Interim CEO, Immunicum
Telephone: +46 8 732 8400
E-mail: info@immunicum.com
Michaela Gertz, CFO, Immunicum
Telephone: +46 8 732 8400
E-mail: info@immunicum.com
| About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving towards late-stage clinical development. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com |
Attachment
